GC203

GC203 is a novel, non-viral vector gene-modified tumor-infiltrating lymphocyte (TIL) therapy developed by Juncell Therapeutics using proprietary DeepTIL cell expansion and NovaGMP gene modification platforms. The therapy involves autologous TILs engineered with self-associating membrane-bound interleukin-7, which helps maintain the stemness of memory T cells, activates internal immune cells, and reduces systemic toxicities. Unlike conventional TIL therapies, GC203 does not require IL-2 administration post-infusion or aggressive lymphodepletion pretreatment. It is administered intravenously and is being investigated for multiple advanced solid tumors including ovarian cancer, endometrial cancer, cervical cancer, breast cancer, gastrointestinal cancers (including pancreatic ductal adenocarcinoma), lung cancer, glioma, and other malignant solid tumors[1][3][5][6][8].

Other names

GC203 TILGC-203 TILGC 203 TILgene-edited GC203 TILautologous genetically modified TIL (GC203)